title: FDA notifications.  Comment period open on combination drugs.
mesh_terms: D006801:Humans; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine